Evidence map›Paper›PMID 38069130›Full record

ArticleInternational journal of molecular sciences2023

CXCR2-Blocking Has Context-Sensitive Effects on Rat Glioblastoma Cell Line Outgrowth (S635) in an Organotypic Rat Brain Slice Culture Depending on Microglia-Depletion (PLX5622) and Dexamethasone Treatment.

Johannes Falter, Annette Lohmeier, Petra Eberl, Eva-Maria Stoerr, Janne Koskimäki, Lena Falter, Jakob Rossmann, Tobias Mederer, Nils Ole Schmidt, Martin Proescholdt

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Therapeutic Potential ofInternational journal of general medicine · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Johannes FalterDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.ORCID 0000-0001-5351-9330
Annette LohmeierDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.
Petra EberlDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.
Eva-Maria StoerrDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.
Janne KoskimäkiDepartment of Neurosurgery, Oulu University Hospital, P.O. Box 25, 90029 Oulu, Finland.ORCID 0000-0002-2311-6327
Lena FalterDepartment of Anesthesiology, Caritas Hospital St. Josef Regensburg, 93053 Regensburg, Germany.
Jakob RossmannDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.ORCID 0009-0009-0885-4717
Tobias MedererDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.ORCID 0000-0002-7274-3546
Nils Ole SchmidtDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.ORCID 0000-0001-6910-8843
Martin ProescholdtDepartment of Neurosurgery, University Hospital Regensburg, 93042 Regensburg, Germany.
University Hospital Regensburg · DECaritas-Krankenhaus St. Josef · DEOulu University Hospital · FI

Funding

Else-Kröner-Fresenius Stiftung 3752914
6 · The paper itself

Abstract

In glioblastoma (GBM), the interplay of different immune cell subtypes, cytokines, and/or drugs shows high context-dependencies. Interrelations between the routinely applied dexamethasone (Dex) and microglia remain elusive. Here, we exploited rat organotypic brain slice co-cultures (OBSC) to examine the effects on a rat GBM cell line (S635) outgrowth resulting from the presence of Dex and pretreatment with the colony-stimulating factor receptor 1 (CSF1-R) inhibitor PLX5622: in native OBSC (without PLX5622-pretreatment), a diminished S635 spheroid outgrowth was observable, whereas Dex-treatment enhanced outgrowth in this condition compared to PLX5622-pretreated OBSC. Screening the supernatants of our model with a proteome profiler, we found that CXCL2 was differentially secreted in a Dex- and PLX5622-dependent fashion. To analyze causal interrelations, we interrupted the CXCL2/CXCR2-axis: in the native OBSC condition, CXCR2-blocking resulted in increased outgrowth, in combination with Dex, we found potentiated outgrowth. No effect was found in the PLX5622-pretreated. Our method allowed us to study the influence of three different factors-dexamethasone, PLX5622, and CXCL2-in a well-controlled, simplified, and straight-forward mechanistic manner, and at the same time in a more realistic ex vivo scenario compared to in vitro studies. In our model, we showed a GBM outgrowth enhancing synergism between CXCR2-blocking and Dex-treatment in the native condition, which was levelled by PLX5622-pretreatment.

Indexed as

GlioblastomaAnimalsBrainCell LineDexamethasoneMicrogliaOrganic ChemicalsRatsDexamethasoneOrganic ChemicalsPLX5622CXCL2danirixindexamethasoneglioblastomamicroglianavarixinOBSCPLX5622

Identifiers

PMID38069130
PMCPMC10706712
OpenAlexW4389057198

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.